Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -37.25 Million SEK | 1.77% |
| 2022 | -37.92 Million SEK | 27.22% |
| 2021 | -52.1 Million SEK | -147.44% |
| 2020 | -21.05 Million SEK | -126.03% |
| 2019 | -9.31 Million SEK | -385171.42% |
| 2018 | -2418.10 SEK | -5.83% |
| 2017 | -2284.97 SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.27 Million SEK | -29.42% |
| 2024 Q3 | -1.63 Million SEK | 91.26% |
| 2024 Q2 | -18.68 Million SEK | -101.34% |
| 2023 Q2 | -14 Million SEK | -96.07% |
| 2023 FY | -32.62 Million SEK | 13.97% |
| 2023 Q4 | -7.16 Million SEK | -22.05% |
| 2023 Q3 | -5.87 Million SEK | 58.06% |
| 2023 Q1 | -7.14 Million SEK | 44.65% |
| 2022 Q3 | -9.88 Million SEK | -6.03% |
| 2022 Q1 | -5.81 Million SEK | 80.0% |
| 2022 FY | -37.92 Million SEK | 27.22% |
| 2022 Q2 | -9.32 Million SEK | -60.28% |
| 2022 Q4 | -12.9 Million SEK | -30.62% |
| 2021 FY | -52.1 Million SEK | -147.44% |
| 2021 Q4 | -29.07 Million SEK | -418.48% |
| 2021 Q3 | -5.6 Million SEK | 50.53% |
| 2021 Q2 | -11.33 Million SEK | -85.99% |
| 2021 Q1 | -6.09 Million SEK | 37.34% |
| 2020 FY | -21.05 Million SEK | -126.03% |
| 2020 Q4 | -9.72 Million SEK | -1046.92% |
| 2020 Q3 | 1.02 Million SEK | 0.0% |
| 2019 FY | -9.31 Million SEK | -385171.42% |
| 2018 FY | -2418.10 SEK | -5.83% |
| 2017 FY | -2284.97 SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 85.038% |
| Ziccum AB (publ) | -21.56 Million SEK | -72.792% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -127.145% |
| BioArctic AB (publ) | 252.64 Million SEK | 114.746% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4308.757% |
| Mendus AB (publ) | -100.65 Million SEK | 62.987% |
| Genovis AB (publ.) | 54.22 Million SEK | 168.704% |
| Intervacc AB (publ) | -93.57 Million SEK | 60.19% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -140.162% |
| Active Biotech AB (publ) | -46.48 Million SEK | 19.856% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 306.863% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 32.775% |
| Aptahem AB (publ) | -10.1 Million SEK | -268.678% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 88.413% |
| Kancera AB (publ) | -65.04 Million SEK | 42.723% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 72.326% |
| Fluicell AB (publ) | -26.87 Million SEK | -38.599% |
| Saniona AB (publ) | -81.06 Million SEK | 54.044% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -201.14% |
| Biovica International AB (publ) | -126.07 Million SEK | 70.45% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 12.354% |
| AcouSort AB (publ) | -17.48 Million SEK | -113.038% |
| Xintela AB (publ) | -57.23 Million SEK | 34.914% |
| Abliva AB (publ) | -96.54 Million SEK | 61.414% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 88.53% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -962.882% |
| OncoZenge AB (publ) | -15.9 Million SEK | -134.272% |
| Amniotics AB (publ) | -29.07 Million SEK | -28.14% |
| 2cureX AB (publ) | -36.36 Million SEK | -2.45% |
| CombiGene AB (publ) | -36.3 Million SEK | -2.614% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -154.467% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 90.308% |
| Camurus AB (publ) | 532.35 Million SEK | 106.998% |
| Corline Biomedical AB | -1.78 Million SEK | -1983.557% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 79.391% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 10.625% |
| I-Tech AB | 24.43 Million SEK | 252.462% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 95.275% |
| Cyxone AB (publ) | -21.66 Million SEK | -71.987% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 64.843% |
| Biosergen AB | -27.26 Million SEK | -36.637% |
| Cantargia AB (publ) | -290.01 Million SEK | 87.155% |
| NextCell Pharma AB | -43.17 Million SEK | 13.708% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 79.391% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -117.907% |
| Nanologica AB (publ) | -69.96 Million SEK | 46.752% |
| SynAct Pharma AB | -224.49 Million SEK | 83.405% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 15.669% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -55.521% |
| LIDDS AB (publ) | -40.67 Million SEK | 8.408% |
| BioInvent International AB (publ) | -369.94 Million SEK | 89.93% |
| Alzinova AB (publ) | -16.52 Million SEK | -125.481% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 85.301% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -482.708% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 67.626% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -84.984% |
| Simris Alg AB (publ) | -36.63 Million SEK | -1.69% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 74.582% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 87.999% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 66.412% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -222.099% |